Last reviewed · How we verify

BUDIPINE — Competitive Intelligence Brief

BUDIPINE (BUDIPINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: budipine. Area: Neuroscience.

phase 2 budipine Potassium voltage-gated channel subfamily H member 2, Glutamate [NMDA] receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

BUDIPINE (BUDIPINE). Budipine works by blocking potassium channels in the brain, which can help regulate abnormal electrical activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BUDIPINE TARGET BUDIPINE phase 2 budipine Potassium voltage-gated channel subfamily H member 2, Glutamate [NMDA] receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (budipine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BUDIPINE — Competitive Intelligence Brief. https://druglandscape.com/ci/budipine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing